The evolution of the conservative approach to breast cancer

Luini, Alberto; Gatti, Giovanna; Zurrida, Stefano; Talakhadze, N.; Brenelli, Fabrício; Gilardi, Daniela; Paganelli, Giovanni; Orecchia, Roberto; Cassano, Enrico; Viale, Giuseppe; Sangalli, Claudia; Ballardini, B.; Santos, Gabriela R.; Veronesi, Umberto

doi:10.1016/j.breast.2006.11.001

Cited by 40 publications

(23 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…89 Because RT has evolved over the years, incorporating new technologies, administration schedules, and delivery of centigray doses, the side effects for contemporary patients may be somewhat lessened, although long-term follow-up is not yet available. 76,[90][91][92][93][94] …”

Section: -61mentioning

confidence: 99%

Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations

Bodai¹,

Tuso

2015

TPJ

286

163

View full text Add to dashboard Cite

Section: -61mentioning

confidence: 99%

Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations

Bodai¹,

Tuso

2015

TPJ

286

163

View full text Add to dashboard Cite

“…Since long-term results of randomized trials have proven the oncological safety of breast-conserving treatment, increasing numbers of breast cancer patients have considered this kind of treatment 2,10 . This increase in the use of breast-conserving treatment led to a rising interest in long-term aesthetic results and patients' quality of life 7 .…”

Section: Discussionmentioning

confidence: 99%

Oncoplastic approach in the conservative treatment of breast cancer: analysis of costs

Lima¹,

Filho

Ribeiro

et al. 2012

Acta Cir. Bras.

View full text Add to dashboard Cite

PURPOSE:To analyze the direct costs of conservative surgical treatment of breast cancer, performed in a university hospital, to the Brazilian National Health Care Public System (SUS), checking the impact of the oncoplastic approach on these costs. METHODS:One hundred thirty eight breast cancer patients who had undergone conservative treatment with oncoplastic approach (n=36) or not (control group, n=102), in the period from 2005 to 2010, were enrolled. Sociodemographic and clinical data were recorded.The direct costs of the surgical procedure were obtained and analyzed. RESULTS:Groups did not differ in regard to age (p=0.963), and patients in oncoplastic group had a longer time of hospital stay (p=0.000). The median direct cost for the oncoplastic group was R$461.00 and for the control group was R$229.00 (p=0.000). CONCLUSION:The oncoplastic approach has generated higher direct costs in conservative surgical treatment of breast cancer to SUS. RESULTADOS:Não houve diferença entre os grupos quanto à idade (p=0.963), e o tempo de internação hospitalar foi maior no grupo oncoplástica (p=0,000). A mediana dos custos diretos do grupo oncoplástica foi de R$461,00 e do grupo controle foi de R$229,00 (p=0,000). CONCLUSÃO:A abordagem oncoplástica gerou custos diretos maiores para o tratamento cirúrgico conservador do câncer mamário pelo SUS.Descritores: Neoplasias da Mama. Mastectomia Segmentar. Cirurgia Plástica. Retalhos Cirúrgicos. Custos de Cuidados de Saúde.Lima DE et al.

show abstract